17:05 EST BiomX files $150M mixed securities shelf
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PHGE:
- BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
- BiomX announces results from Part 2 of the Phase 1b/2a trial of BX004
- BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update
- PHGE Upcoming Earnings Report: What to Expect?
- BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference